Stay updated on Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial

Sign up to get notified when there's something new on the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:39:41.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the ongoing Phase 3 study comparing Daratumumab, VELCADE, Lenalidomide, and Dexamethasone (D-VRd) versus VELCADE, Lenalidomide, and Dexamethasone (VRd) in subjects with previously untreated multiple myeloma.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:55.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to provide detailed eligibility criteria for study participants, including specific health conditions and prior treatments required for inclusion. This change offers more comprehensive information for potential participants and researchers about the study's requirements.
    Difference
    58%
    Check dated 2024-05-22T21:23:03.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T21:44:59.000Z thumbnail image

Stay in the know with updates to Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page.